Compare CRSR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | CDNA |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2007 |
| Metric | CRSR | CDNA |
|---|---|---|
| Price | $10.27 | $23.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $8.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 3.8M | 582.4K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | N/A |
| EPS | ★ 0.11 | 0.05 |
| Revenue | ★ $1,472,480,000.00 | $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | $6.90 | $11.31 |
| P/E Ratio | ★ $95.23 | $446.20 |
| Revenue Growth | 11.86 | ★ 18.93 |
| 52 Week Low | $4.48 | $10.96 |
| 52 Week High | $13.10 | $23.24 |
| Indicator | CRSR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 68.05 |
| Support Level | $5.30 | $15.80 |
| Resistance Level | $13.10 | N/A |
| Average True Range (ATR) | 0.87 | 1.01 |
| MACD | 0.24 | 0.11 |
| Stochastic Oscillator | 55.98 | 92.51 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the United States (U.S.), Americas (excluding U.S.) , Europe and the Middle East, and the Asia Pacific, of which maximum revenue is generated from United States (U.S.).
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.